Arrayjet Launches Outsourced Microarray Service
News Apr 22, 2016
Arrayjet has launched a pioneering in-house consultancy service designed to meet the needs of research laboratories across the globe requiring an outsourced fully time-scaled microarray printing facility. Called Arrayjet Advance™, the initiative has been developed to offer life science companies and research labs a dedicated microarray analytical results service by providing access to Arrayjet’s in-house scientific team and fully automated laboratory complex.
The service will produce fast, reproducible and precision-accurate microarray analytics through Arrayjet’s novel inkjet technology and instrumentation processes for a broad spectrum of diagnostic applications.
Dr Iain McWilliam, Chief Executive Officer, Arrayjet's comments, ''We understand that the life sciences and healthcare industries need high-end, high quality, fast paced research and that microarrays are one of the key tools used to get accurate results. We believe by developing our strategy to become a complete solutions provider through the creation of Arrayjet Advance, we are better placed to help our customers achieve good quality data on which to make decisions, by either providing an instrument, printed slides or a full microarray service with data analysis.
“We are seeing an increasing number of research laboratories looking to adopt microarray technology and as Arrayjet has accumulated considerable experience in helping purchasers of our instrumentation technology to prepare microarrays, this trend provided us with an opportunity to start an unrivalled outsourced contract service for printing microarrays to customer specifications. I believe this to be a great value-add service for the broader life sciences industry.”
Arrayjet’s microarray technology prints high-density arrays of microscopic spots of biological solutions on to solid substrates that can be used as diagnostic devices for healthcare and high-throughput screening tools for the life sciences diagnostics market, where it supports a variety of genomic, proteomic and glycomic applications.
Researchers have developed an artificial enzymatic pathway for synthesizing isoprenoids, or terpenes, in E. coli. This shorter, more efficient, cost-effective and customizable pathway transforms E. coli into a factory that can produce terpenes for use in everything from cancer drugs to biofuels.READ MORE
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019